Abstract: The present application is directed to a method of treating central nervous system disorders originating as a consequence of head injury or brain ischemia. The method comprises administering an effective amount of cyclo-(L-alanyl-1-amino-1-cyclopentane carbonyl) to treat a central nervous system disorder in a mammalian organism in need of such treatment. The administration may be conducted either orally or parenterally.

Abstract: A cell-protective composition for preventing or treating of a peptic ulcer due to topical endogenous lesion of gastric or duodenal mucous membrane comprises as a physiologically active component the cyclo-(1-alanyl-amino-1-cyclopentanecarbonyl)cyclodipeptide. The subject composition is designated for administration by oral or parenteral route. It is substantially non-toxic and well tolerated, and acts beneficially, even at low dosage level.

Abstract: The claimed invention concerns concentrates of coagulation factors II, VII, IX and X and the method of their preparation by selective adsorption on an equilibrated carrier of hydroxyethylmethacrylate or hydroxyethylacrylate with bound diethylaminoethyl groups, followed by selective elution.The concentrates of coagulation factors II and X can be used to detect coagulation factor VII and in a laboratory method for the detection or determination of the extent of mammalian inflammatory diseases.

Abstract: Peptide ester and amide derivatives of the general formula I: ##STR1## in which X is H or an acyl, A and B are structurally defined amino acid residues, n is an integer of from 1 to 3, R.sup.1 is H or a lower alkyl and either R.sup.2 or C is a defined optionally modified amino acid residue and the other is a lower alkoxyl, an amino group or a direct chemical bond, are converted under physiologic conditions, by enzymic hydrolysis in pathologically altered tissues and subsequent spontaneous cyclization, into pharmacodynamically active spirocyclic peptide derivatives of the general formula III: ##STR2## in which R.sup.3 and R.sup.4 are H atoms, optionally substituted alkyl groups or jointly an aliphatic chain forming preferably a 2,5- piperazinedione ring, and hence can act as pro-farmaca (drug precursors) of prolonged biological effect.

Abstract: Novel peptide analogs of the serum thymic factor are disclosed, structurally modified, in comparison with the natural substance, both in their N-terminal and C-terminal parts and inside the amino-acid sequence, corresponding to the general formula IA-Gly-Gly-Ser-Asn-B-C-NH-R (I),in which A is pGlu, Gln, Ala-Lys-Ser-Gln, pGlu-Ala-Lys-Ser-Gln or Gln-Ala-Lys-Ser-Gln, B and C are Gly, Phe, Leu, Ala or a direct bond, and R is H, an alkyl with 1 to 6 carbon atoms or a 2-phenylethyl. Depending upon their chemical structure, the subject thymic factor analogs possess either agonistic (immunostimulative) or antagonistic (immunosuppressory) properties.

Abstract: A method is described for the preparation of novel alkylamides of carboxyalkanoyl peptides of the formula ##STR1## wherein R is an aralky or an alkyl group of 1-5 carbon atoms, A is a residue of peptidically bound proline or alanine, B is a straight bond or a residue of peptidically bound proline or alanine and X is a CH.dbd.CH group or a methylene group of 1-3 carbon atoms.The described compounds are capable of inhibiting elastase.

Abstract: This invention relates to biologically active tripeptide and tetrapeptide alkylamides of the general formula ##STR1## wherein R.sup.1 is an alkyl with 1 to 5 carbon atoms,A is a peptidically bound alanine or proline residue,B is a peptidically bound glycine, alanine or proline residue,n is an integer of 1 or 2, andR.sup.2 is an alkylcarbonylamino group with 2 to 12 carbon atoms, an alkenyl with 6 to 12 carbon atoms or a benzyloxycarbonylamino group.The compounds effectively inhibit the enzymatic activity of pancreatic and leucocytal elastase and are expected to find use in the treatment of acute pancreatitis, chronic obstructive pulmonary disease, pulmonary emphysema, and certain forms of arthritis. The invention also relates to processes for the preparation of the title compounds and to pharmaceutical compositions containing them.